Gepotidacin mesylate is a Small Molecule owned by GSK, and is involved in 21 clinical trials, of which 17 were completed, 3 are ongoing, and 1 is planned.

Gepotidacin mesylate (GSK-2140944) is a triazaacenaphthylene bacterial type II topoisomerase II, IV and DNA gyrase inhibitor. They are molecular machines that regulate DNA supercoiling and separate interlocked chromosomes. Topoisomerases resolve the topological problems of DNA by transiently cleaving both strands of a DNA duplex to form a cleavage complex through which another DNA segment can be transported. Topoisomerase is the second most abundant chromatin protein after histones and its biological roles include the decatenation of newly replicated DNA and the relaxation of polymerase-driven supercoils.

The revenue for Gepotidacin mesylate is expected to reach a total of $2.8bn through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Gepotidacin mesylate NPV Report.

Gepotidacin mesylate is originated and owned by GSK.

Gepotidacin mesylate Overview

Gepotidacin mesylate (GSK-2140944) is under development for the treatment of uncomplicated urinary tract infection (acute cystitis) and Gram-negative bacterial infections like uncomplicated urogenital gonorrhea caused by neisseria gonorrhoeae and other bacterial infections. The drug candidate is administered orally as a capsule, tablet and intravenously as an infusion. It belongs to the bacterial topoisomerase type II, IV and DNA gyrase inhibitor (BTI) class of antibiotics. It is a new molecular entity. It was also under development for gram-positive acute bacterial skin and skin structure infections (ABSSSI), anthrax, plague and tularemia.

GSK Overview

GSK is a healthcare company that focuses on developing, manufacturing and commercializing pharmaceuticals, vaccines and consumer healthcare products. It offers drugs for the treatment of diseases such as HIV, respiratory, cancer, immuno-inflammation, anti-viral, central nervous system (CNS), metabolic, cardiovascular and urogenital, anti-bacterials, dermatology and rare diseases. The company also offers over-the-counter (OTC) products for pain relief, oral health, nutrition, skin health and gastro-intestinal diseases. GSK’s vaccine portfolio covers various diseases including hepatitis, diphtheria, tetanus, whooping cough, rotavirus and HPV infections, measles and bacterial meningitis, among others. The company sells its products through wholesalers, pharmacies, hospitals, physicians and other groups worldwide. GSK is headquartered in Brentford, Middlesex, the UK.

The company reported revenues of (British Pounds) GBP34,114 million for the fiscal year ended December 2021 (FY2021), an increase of 0% over FY2020. In FY2021, the company’s operating margin was 18.1%, compared to an operating margin of 22.8% in FY2020. In FY2021, the company recorded a net margin of 12.9%, compared to a net margin of 16.9% in FY2020. The company reported revenues of GBP7,829 million for the third quarter ended September 2022, an increase of 13% over the previous quarter.

Quick View – Gepotidacin mesylate

Report Segments
  • Innovator
Drug Name
  • Gepotidacin mesylate
Administration Pathway
  • Intravenous
  • Oral
Therapeutic Areas
  • Genito Urinary System And Sex Hormones
  • Infectious Disease
Key Companies
  • Sponsor Company: GSK
  • Originator: GSK
Highest Development Stage
  • Phase III

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate rNPV, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA)and phase transition success rate(PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.